Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828747 · ClinicalTrials.gov registry record · Phase 2
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT03828747 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 272 participants.
The verdict
NCT03828747, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to two study cohorts.
Interventions
- DRUG Placebo
- DRUG [18F]GTP1
- DRUG Semorinemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828747
The ClinicalTrials.gov registry entry for NCT03828747 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03828747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828747 about?
NCT03828747 is a clinical study titled "A Study of Semorinemab in Patients With Moderate Alzheimer's Disease". This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, a...
What is the current status of trial NCT03828747?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2019-01-25. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT03828747?
The interventions under investigation include: Placebo (DRUG), [18F]GTP1 (DRUG), Semorinemab (DRUG).
Who is sponsoring clinical trial NCT03828747?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.